BRPI0915908A2 - derivado de pirimidil sulfonamida e seu uso para o tratamento de doenças mediadas por quimiocina - Google Patents
derivado de pirimidil sulfonamida e seu uso para o tratamento de doenças mediadas por quimiocinaInfo
- Publication number
- BRPI0915908A2 BRPI0915908A2 BRPI0915908A BRPI0915908A BRPI0915908A2 BR PI0915908 A2 BRPI0915908 A2 BR PI0915908A2 BR PI0915908 A BRPI0915908 A BR PI0915908A BR PI0915908 A BRPI0915908 A BR PI0915908A BR PI0915908 A2 BRPI0915908 A2 BR PI0915908A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- mediated diseases
- sulfonamide derivative
- chemokine mediated
- pyrimidyl
- Prior art date
Links
- 102000019034 Chemokines Human genes 0.000 title 1
- 108010012236 Chemokines Proteins 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- WJJBIYLGJUVNJX-UHFFFAOYSA-N pyrimidine-2-sulfonamide Chemical class NS(=O)(=O)C1=NC=CC=N1 WJJBIYLGJUVNJX-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/69—Benzenesulfonamido-pyrimidines
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8121308P | 2008-07-16 | 2008-07-16 | |
| PCT/GB2009/050856 WO2010007427A1 (en) | 2008-07-16 | 2009-07-15 | Pyrimidyl sulfonaminde derivative and its use for the treatment of chemokine mediated diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0915908A2 true BRPI0915908A2 (pt) | 2018-07-10 |
Family
ID=41011976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0915908A BRPI0915908A2 (pt) | 2008-07-16 | 2009-07-15 | derivado de pirimidil sulfonamida e seu uso para o tratamento de doenças mediadas por quimiocina |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20100016275A1 (enExample) |
| EP (1) | EP2315754A1 (enExample) |
| JP (1) | JP2011528030A (enExample) |
| KR (1) | KR20110031462A (enExample) |
| CN (1) | CN102159555A (enExample) |
| AR (1) | AR072818A1 (enExample) |
| AU (1) | AU2009272425B2 (enExample) |
| BR (1) | BRPI0915908A2 (enExample) |
| CA (1) | CA2730477A1 (enExample) |
| MX (1) | MX2011000402A (enExample) |
| RU (1) | RU2011101661A (enExample) |
| TW (1) | TW201006824A (enExample) |
| WO (1) | WO2010007427A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2007002240A (es) * | 2004-08-28 | 2007-04-20 | Astrazeneca Ab | Derivados de pirimidinosulfonamida como moduladores del receptor quimiocina. |
| SG186859A1 (en) | 2010-07-13 | 2013-02-28 | Astrazeneca Ab | New crystalline forms of n-[2-[[(2,3-difluoropheny)methyl)thio]-6-{[(1r,2s)-2,3-dihydroxy-1- methylpropyl]oxy}-4-pyrimidinyl]-1-azetidinesulfonamide |
| PE20181069A1 (es) | 2011-07-12 | 2018-07-04 | Astrazeneca Ab | N-(6-((2r,3s)-3,4-dihidroxibutan-2-iloxi)-2-(4-fluorobenciltio)pirimidin-4-il)-3-metilacetidina-1-sulfonamida como modulador del receptor de quimiocina |
| JP6096808B2 (ja) * | 2012-02-07 | 2017-03-15 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 新規なアゼチジン誘導体 |
| US9013997B2 (en) | 2012-06-01 | 2015-04-21 | Broadcom Corporation | System for performing distributed data cut-through |
| AU2017231832B2 (en) | 2016-03-11 | 2021-11-11 | Ardea Biosciences, Inc. | CXCR-2 inhibitors for treating crystal arthropathy disorders |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2540356A (en) * | 1949-03-12 | 1951-02-06 | Sharp & Dohme Inc | Sulfonamide derivatives |
| GB866843A (en) * | 1958-12-08 | 1961-05-03 | Ici Ltd | Sulphonamidopyrimidines |
| NL279406A (enExample) * | 1961-06-16 | |||
| NL302745A (enExample) * | 1962-12-29 | |||
| US3457278A (en) * | 1964-10-15 | 1969-07-22 | Geigy Chem Corp | Cyclopropyl-4-sulfanilamido-pyrimidines |
| US3452018A (en) * | 1966-08-29 | 1969-06-24 | American Home Prod | 1 - (2 - substituted - 6 - arylsulfonamidopyrimidin - 4 - yl)pyridinium hydroxide inner salts |
| US3673184A (en) * | 1970-09-02 | 1972-06-27 | Dainippon Pharmaceutical Co | Certain 2-substituted-5,8-dihydro-5-oxopyrido{8 2,3-d{9 pyrimidine-6-carboxylic acid derivatives |
| GB2359551A (en) * | 2000-02-23 | 2001-08-29 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
| GB0217431D0 (en) * | 2002-07-27 | 2002-09-04 | Astrazeneca Ab | Novel compounds |
| ATE381546T1 (de) * | 2002-08-24 | 2008-01-15 | Astrazeneca Ab | Pyrimidinderivate als modulatoren der aktivitut von chemokinrezeptoren |
| GB0401269D0 (en) * | 2004-01-21 | 2004-02-25 | Astrazeneca Ab | Compounds |
| GB0419235D0 (en) * | 2004-08-28 | 2004-09-29 | Astrazeneca Ab | Compounds |
| MX2007002240A (es) * | 2004-08-28 | 2007-04-20 | Astrazeneca Ab | Derivados de pirimidinosulfonamida como moduladores del receptor quimiocina. |
| JP2006137723A (ja) * | 2004-11-15 | 2006-06-01 | Kyowa Hakko Kogyo Co Ltd | スルホンアミド誘導体 |
-
2009
- 2009-07-15 JP JP2011518009A patent/JP2011528030A/ja active Pending
- 2009-07-15 TW TW098123883A patent/TW201006824A/zh unknown
- 2009-07-15 WO PCT/GB2009/050856 patent/WO2010007427A1/en not_active Ceased
- 2009-07-15 RU RU2011101661/04A patent/RU2011101661A/ru not_active Application Discontinuation
- 2009-07-15 CN CN2009801361926A patent/CN102159555A/zh active Pending
- 2009-07-15 EP EP09785332A patent/EP2315754A1/en not_active Withdrawn
- 2009-07-15 MX MX2011000402A patent/MX2011000402A/es not_active Application Discontinuation
- 2009-07-15 US US12/503,433 patent/US20100016275A1/en not_active Abandoned
- 2009-07-15 KR KR1020117000994A patent/KR20110031462A/ko not_active Withdrawn
- 2009-07-15 BR BRPI0915908A patent/BRPI0915908A2/pt not_active IP Right Cessation
- 2009-07-15 CA CA2730477A patent/CA2730477A1/en not_active Abandoned
- 2009-07-15 AU AU2009272425A patent/AU2009272425B2/en not_active Ceased
- 2009-07-16 AR ARP090102722A patent/AR072818A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2315754A1 (en) | 2011-05-04 |
| AU2009272425B2 (en) | 2012-02-02 |
| AR072818A1 (es) | 2010-09-22 |
| AU2009272425A1 (en) | 2010-01-21 |
| WO2010007427A1 (en) | 2010-01-21 |
| CN102159555A (zh) | 2011-08-17 |
| MX2011000402A (es) | 2011-03-15 |
| US20100016275A1 (en) | 2010-01-21 |
| KR20110031462A (ko) | 2011-03-28 |
| CA2730477A1 (en) | 2010-01-21 |
| RU2011101661A (ru) | 2012-08-27 |
| TW201006824A (en) | 2010-02-16 |
| JP2011528030A (ja) | 2011-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012004970A2 (pt) | inibidores de jak2 e seu uso para o tratamento de doenças mieloproliferativas e câncer | |
| BR112013013898A2 (pt) | compostos de pirimidinona para o uso no tratamento de doenças ou condições mediadas por lp-pla2 | |
| BRPI0919004A2 (pt) | composto de multiheteroarila como inibidores de h-pgds e sua utilização para o tratamento de doenças mediadas por prostaglandina d2 | |
| PT2709989T (pt) | Derivados de quinazolina para o tratamento de infeções virais e outras doenças | |
| BRPI0807717A2 (pt) | Inibidores de quinase úteis para o tratamento de doenças mieloproliferativas e outras doenças proliferativas. | |
| BRPI0716844A2 (pt) | Inidores de quinase úteis para o tratamento de doenças proliferativas | |
| BRPI0914341A2 (pt) | artigos absorventes descartáveis para sexo específico | |
| BRPI1013698A2 (pt) | métodos para tratamento com o uso de terapia de combinação | |
| SMT201600398B (it) | Inibitori di proteina chinasi (varianti), uso di questi nel trattamento di malattie oncologiche e composizione farmaceutica basata su questi | |
| BRPI0911923A2 (pt) | dispositivos filamentosos para o tratamento de defeitos vasculares | |
| BRPI0813105A2 (pt) | Derivado de sulfonamida de ácido malônico e uso faramacêutico do mesmo | |
| PT2367561E (pt) | Composições e métodos para o tratamento da doença celíaca | |
| BRPI0813212A2 (pt) | Métodos de tratamento de doenças e distúrbios mediados por serotonina | |
| BRPI0819241A2 (pt) | Compostos derivados de amina para o tratamento de distúrbios e doenças oftálmicas | |
| BRPI0819073A2 (pt) | fralda descartável | |
| BRPI0816712A2 (pt) | terapia de intervalo para o tratamento de tinnitus | |
| SMT201800509T1 (it) | Uso di inibitori di pde7 per il trattamento di disturbi del movimento | |
| BRPI0911577A2 (pt) | derivados espiro-indol para o tratamento de doenças parasíticas. | |
| IL209336B (en) | Compositions for treating hyperproliferative diseases and uses thereof | |
| BR112012002265A2 (pt) | composições farmacêuticas para o tratamento de câncer e outras doenças ou distúrbios | |
| BRPI0819071A2 (pt) | fralda descartável | |
| BR112014016389A8 (pt) | composições e uso das mesmas para o tratamento de distúrbios e doenças hepáticas | |
| BRPI0912687A2 (pt) | uso de bactéria probiótica para o tratamento de hiperhomocisteinaemia | |
| BRPI0917440A2 (pt) | composições farmacêuticas oftálmicas para o tratamento de patologias neoangiogênicas do olho | |
| BRPI0812750A2 (pt) | Medicamento compreendendo uma combinação de substância ativa para tratamento de sintomas de alergia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application fees: application dismissed [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2480 DE 17-07-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |